Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
November 22, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
November 10, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Participate in the Jefferies London Healthcare Conference
November 09, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
November 08, 2022 08:00 ET
|
Akari Therapeutics Plc
Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials across a broad range of therapeutic areas, including specialty and...
Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference
October 31, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
October 28, 2022 16:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
September 27, 2022 08:00 ET
|
Akari Therapeutics Plc
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports Akari’s focused pipeline...
Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
September 22, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
September 12, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Narrows Pipeline Focus
August 01, 2022 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...